Alpha 2.0
Login Register
» Authors » P A Rowlings

P A Rowlings

Explore the profile of P A Rowlings including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 52
Citations 1756
Followers 0
Related Specialties
Hematology
General Surgery
General Medicine
Top 10 Co-Authors
M M Horowitz
R P Gale
K A Sobocinski
J P Klein
M J Zhang
J R Passweg
J O Armitage
M M BORTIN
H M Lazarus
R H Herzig
Published In
Bone Marrow Transplant
Blood
J Clin Oncol
Clin Transpl
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome
Lechowicz M, Lazarus H, Carreras J, Laport G, Cutler C, Wiernik P, et al.
Bone Marrow Transplant . 2014 Jul; 49(11):1360-5. PMID: 25068422
We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood...
2.
The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia
Miller C, Rowlings P, Zhang M, Jones R, Piantadosi S, Keating A, et al.
Exp Hematol . 2001 Nov; 29(11):1336-46. PMID: 11698130
Background: Autologous bone marrow transplantation is an important therapy for patients with acute myelogenous leukemia (AML). However, leukemia in the graft may contribute to posttransplant relapse. Treatment of the graft...
3.
Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program
Filipovich A, Stone J, Tomany S, Ireland M, Kollman C, Pelz C, et al.
Blood . 2001 Mar; 97(6):1598-603. PMID: 11238097
Human leukocyte antigen (HLA)-identical sibling bone marrow transplantation is an effective treatment for Wiskott-Aldrich syndrome. However, most children with this disease lack such donors and many patients receive transplants from...
4.
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry
Vose J, Zhang M, Rowlings P, Lazarus H, Bolwell B, Freytes C, et al.
J Clin Oncol . 2001 Feb; 19(2):406-13. PMID: 11208832
Purpose: To evaluate the results of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (autotransplants) in patients with diffuse aggressive non-Hodgkin's lymphoma (NHL) who never achieve a complete remission with conventional...
5.
Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission
Tallman M, Rowlings P, Milone G, Zhang M, Perez W, Weisdorf D, et al.
Blood . 2000 Aug; 96(4):1254-8. PMID: 10942365
Allogeneic bone marrow transplantation is an effective postremission strategy for patients with acute myelogenous leukemia (AML) in first complete remission (CR). The value of administering consolidation chemotherapy before human leukocyte...
6.
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities
Champlin R, Passweg J, Zhang M, Rowlings P, Pelz C, Atkinson K, et al.
Blood . 2000 Jun; 95(12):3996-4003. PMID: 10845940
T-cell depletion of donor marrow decreases graft-versus-host disease resulting from transplants from unrelated and human leukocyte antigen (HLA)-mismatched related donors. However, there are diverse strategies for T-cell-depleted transplantation, and it...
7.
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT)
Champlin R, Schmitz N, Horowitz M, Chapuis B, Chopra R, Cornelissen J, et al.
Blood . 2000 Jun; 95(12):3702-9. PMID: 10845900
Peripheral blood cells are increasingly used in place of bone marrow as a source of hematopoietic stem cells for allogeneic transplantation. The relative efficacy of these 2 approaches is unknown....
8.
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia
Socie G, Curtis R, Deeg H, Sobocinski K, Filipovich A, Travis L, et al.
J Clin Oncol . 2000 Jan; 18(2):348-57. PMID: 10637249
Purpose: To determine the incidence of and risk factors for second malignancies after allogeneic bone marrow transplantation (BMT) for childhood leukemia. Patients And Methods: We studied a cohort of 3,...
9.
Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry
Giralt S, Szydlo R, Goldman J, BIGGS J, Herzig R, Klein J, et al.
Blood . 2000 Jan; 95(2):410-5. PMID: 10627443
Allogeneic bone marrow transplantation (BMT) is the only curative therapy for chronic myelogenous leukemia (CML), though several studies indicate that prolonged survival can result from interferon-alpha (IFN-alpha) treatment. IFN-alpha is...
10.
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer
Rowlings P, Williams S, Antman K, Fields K, Fay J, Reed E, et al.
JAMA . 1999 Oct; 282(14):1335-43. PMID: 10527180
Context: Women with breast cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autotransplants) in North America. Despite widespread use, controversy exists about...